Novel drugs lift Sino Biopharm earnings, easing price-cap pain
The pharmaceutical company posted an 11% rise in half-year revenue, helped by growing income from innovative medicines, as it pivots away from the generic drug business Key Takeaways: Revenue from…
Recent Articles
RELATED ARTICLES
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
